Armata Pharmaceuticals (ARMP) Stock Overview
Operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ARMP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Armata Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.12 |
| 52 Week High | US$3.14 |
| 52 Week Low | US$0.90 |
| Beta | 1.13 |
| 1 Month Change | 9.47% |
| 3 Month Change | 52.94% |
| 1 Year Change | 30.01% |
| 3 Year Change | -24.09% |
| 5 Year Change | -1.62% |
| Change since IPO | -32.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARMP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.7% | 5.2% | 1.2% |
| 1Y | 30.0% | -0.3% | 17.7% |
Return vs Industry: ARMP exceeded the US Biotechs industry which returned -0.3% over the past year.
Return vs Market: ARMP exceeded the US Market which returned 17.7% over the past year.
Price Volatility
| ARMP volatility | |
|---|---|
| ARMP Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ARMP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ARMP's weekly volatility has decreased from 15% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 60 | Deborah Birx | www.armatapharma.com |
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Armata Pharmaceuticals, Inc. Fundamentals Summary
| ARMP fundamental statistics | |
|---|---|
| Market cap | US$113.04m |
| Earnings (TTM) | -US$25.71m |
| Revenue (TTM) | US$6.87m |
Is ARMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARMP income statement (TTM) | |
|---|---|
| Revenue | US$6.87m |
| Cost of Revenue | US$34.54m |
| Gross Profit | -US$27.67m |
| Other Expenses | -US$1.96m |
| Earnings | -US$25.71m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | -402.88% |
| Net Profit Margin | -374.30% |
| Debt/Equity Ratio | -161.6% |
How did ARMP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 12:17 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Armata Pharmaceuticals, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | H.C. Wainwright & Co. |